David M Taylor

Summary

Affiliation: Institute of Psychiatry
Country: UK

Publications

  1. ncbi request reprint Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review
    David M Taylor
    Maudsley Hospital, London, United Kingdom
    J Clin Psychiatry 64:30-4. 2003
  2. ncbi request reprint Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome
    David M Taylor
    Pharmacy Department, Maudsley Hospital, London, UK
    Int J Neuropsychopharmacol 9:685-94. 2006
  3. ncbi request reprint Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice
    David M Taylor
    Pharmacy Department, Maudsley Hospital, London, UK
    J Clin Psychiatry 70:196-200. 2009
  4. ncbi request reprint Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients
    David M Taylor
    Pharmacy Department, Maudsley Hospital, London, United Kingdom
    J Clin Psychiatry 65:1076-83. 2004
  5. ncbi request reprint Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis
    David M Taylor
    Maudsley Hospital, Denmark Hill, London, UK
    J Clin Psychiatry 64:589-97. 2003
  6. ncbi request reprint Outcome following clozapine discontinuation: a retrospective analysis
    James M Atkinson
    South London and Maudsley National Health Service NHS Trust, Pharmacy Department, Maudsley Hospital, London, United Kingdom
    J Clin Psychiatry 68:1027-30. 2007
  7. doi request reprint Plasma concentrations of quetiapine, N-desalkylquetiapine, o-desalkylquetiapine, 7-hydroxyquetiapine, and quetiapine sulfoxide in relation to quetiapine dose, formulation, and other factors
    Danielle S Fisher
    Toxicology Unit, Department of Clinical Biochemistry, Bessemer Wing, King s College Hospital NHS Foundation Trust, London, United Kingdom
    Ther Drug Monit 34:415-21. 2012
  8. ncbi request reprint Prognostic indicators for early discontinuation of risperidone long-acting injection
    Maxine X Patel
    Division of Psychological Medicine, Institute of Psychiatry and GKT School of Medicine, De Crespigny Park, London, UK
    Int Clin Psychopharmacol 19:233-9. 2004
  9. pmc A UK audit of screening for the metabolic side effects of antipsychotics in community patients
    Thomas R E Barnes
    Department of Psychological Medicine, Imperial College Faculty of Medicine, Charing Cross Campus, London W6 8RP, UK
    Schizophr Bull 33:1397-403. 2007
  10. ncbi request reprint Prolongation of QTc interval and antipsychotics
    David M Taylor
    Am J Psychiatry 159:1062; author reply 1064. 2002

Detail Information

Publications10

  1. ncbi request reprint Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review
    David M Taylor
    Maudsley Hospital, London, United Kingdom
    J Clin Psychiatry 64:30-4. 2003
    ..It is thought that only clozapine is likely to be effective in such cases and that other drugs are ineffective. We sought to discover prior patterns of antipsychotic prescribing in schizophrenic patients eventually prescribed clozapine...
  2. ncbi request reprint Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome
    David M Taylor
    Pharmacy Department, Maudsley Hospital, London, UK
    Int J Neuropsychopharmacol 9:685-94. 2006
    ..61, p=0.001). Overall outcome of RLAI treatment is moderately good but better still when prescribed because of prior poor adherence and for more elderly patients. RLAI is less suitable for those who have previously received clozapine...
  3. ncbi request reprint Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice
    David M Taylor
    Pharmacy Department, Maudsley Hospital, London, UK
    J Clin Psychiatry 70:196-200. 2009
    ..To evaluate outcomes of clinical use of risperidone long-acting injection (RLAI) and determine factors predicting continuation with treatment...
  4. ncbi request reprint Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients
    David M Taylor
    Pharmacy Department, Maudsley Hospital, London, United Kingdom
    J Clin Psychiatry 65:1076-83. 2004
    ..The use of risperidone long-acting injection (RLAI) is reasonably well supported by controlled studies. Little is known about treatment outcomes in patients receiving RLAI in clinical practice...
  5. ncbi request reprint Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis
    David M Taylor
    Maudsley Hospital, Denmark Hill, London, UK
    J Clin Psychiatry 64:589-97. 2003
    ..This study was designed as a cost analysis study comparing costs and basic clinical outcomes of treatment with risperidone or olanzapine in a naturalistic setting...
  6. ncbi request reprint Outcome following clozapine discontinuation: a retrospective analysis
    James M Atkinson
    South London and Maudsley National Health Service NHS Trust, Pharmacy Department, Maudsley Hospital, London, United Kingdom
    J Clin Psychiatry 68:1027-30. 2007
    ..Our aim was to establish medium-term outcome in patients stopping clozapine in normal clinical practice...
  7. doi request reprint Plasma concentrations of quetiapine, N-desalkylquetiapine, o-desalkylquetiapine, 7-hydroxyquetiapine, and quetiapine sulfoxide in relation to quetiapine dose, formulation, and other factors
    Danielle S Fisher
    Toxicology Unit, Department of Clinical Biochemistry, Bessemer Wing, King s College Hospital NHS Foundation Trust, London, United Kingdom
    Ther Drug Monit 34:415-21. 2012
    ....
  8. ncbi request reprint Prognostic indicators for early discontinuation of risperidone long-acting injection
    Maxine X Patel
    Division of Psychological Medicine, Institute of Psychiatry and GKT School of Medicine, De Crespigny Park, London, UK
    Int Clin Psychopharmacol 19:233-9. 2004
    ..RLAI discontinuation is high early on but subsequently tapers off. Preceding antipsychotic type (depot versus oral) is a stronger prognostic indicator than treatment refractoriness for RLAI discontinuation...
  9. pmc A UK audit of screening for the metabolic side effects of antipsychotics in community patients
    Thomas R E Barnes
    Department of Psychological Medicine, Imperial College Faculty of Medicine, Charing Cross Campus, London W6 8RP, UK
    Schizophr Bull 33:1397-403. 2007
    ....
  10. ncbi request reprint Prolongation of QTc interval and antipsychotics
    David M Taylor
    Am J Psychiatry 159:1062; author reply 1064. 2002